HC Wainwright Increases Earnings Estimates for XOMA Royalty

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimate for XOMA Royalty to $0.21 per share, up from $0.03, maintaining a "Buy" rating with a price target of $104.00.
• XOMA reported a Q2 2025 EPS of $0.48, surpassing the consensus estimate of (0.12) by $0.60, with revenues of $13.13 million exceeding expectations.
• Institutional investors control approximately 95.92% of XOMA's stock, with significant recent increases in holdings from firms like GAMMA Investing LLC and Renaissance Technologies LLC.

XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) - HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of XOMA Royalty in a research note issued on Thursday, August 21st. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $0.21 for the quarter, up from their previous forecast of $0.03. HC Wainwright currently has a "Buy" rating and a $104.00 target price on the stock. The consensus estimate for XOMA Royalty's current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for XOMA Royalty's Q4 2025 earnings at $0.24 EPS and FY2025 earnings at $1.17 EPS.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.60. The firm had revenue of $13.13 million during the quarter, compared to the consensus estimate of $9.39 million. XOMA Royalty had a negative net margin of 27.57% and a positive return on equity of 2.63%.

A number of other equities research analysts also recently weighed in on the stock. Zacks Research upgraded shares of XOMA Royalty to a "hold" rating in a research report on Tuesday, August 12th. Wall Street Zen upgraded shares of XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Monday, August 11th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, XOMA Royalty has a consensus rating of "Moderate Buy" and an average price target of $69.50.

XOMA Royalty Stock Performance

XOMA stock traded down $0.01 during mid-day trading on Monday, hitting $32.70. 1,099 shares of the company were exchanged, compared to its average volume of 44,460. The business has a 50 day simple moving average of $27.93 and a 200-day simple moving average of $24.78. The company has a current ratio of 4.88, a quick ratio of 4.88 and a debt-to-equity ratio of 1.41. The stock has a market capitalization of $395.28 million, a PE ratio of -21.09 and a beta of 1.00. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $35.22.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in XOMA Royalty by 1,063.8% in the first quarter. GAMMA Investing LLC now owns 1,734 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 1,585 shares during the last quarter. Nuveen Asset Management LLC grew its stake in shares of XOMA Royalty by 3.8% during the fourth quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company's stock worth $377,000 after buying an additional 527 shares during the last quarter. Northern Trust Corp grew its stake in shares of XOMA Royalty by 1.5% during the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock worth $2,396,000 after buying an additional 1,340 shares during the last quarter. Bank of America Corp DE grew its stake in shares of XOMA Royalty by 34.7% during the fourth quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company's stock worth $205,000 after buying an additional 2,009 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of XOMA Royalty by 89.8% during the fourth quarter. Renaissance Technologies LLC now owns 16,100 shares of the biotechnology company's stock worth $423,000 after buying an additional 7,619 shares during the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.